Views: 1,461 | Downloads:
124
| Responses: 0
XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Photodynamic Therapy for AMD and Non-AMD Patients: Two-Year Results in Thais
Objective: To determine the long-term effect of photodynamic therapy (PDT) with verteporfin for age-related
macular degeneration (AMD) and non-AMD in Thailand and to compare with the Treatment of Age-Related
Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP)
study.
Material and Method: The data of patients who received PDT between July 2003 and December 2004 and had
completed two-year follow-up were prospectively reviewed. Treated eyes were classified into two main groups,
the AMD (group 1) and non-AMD (group 2) groups. The AMD group was further divided into three
subgroups, group1A, AMD with subfoveal choroidal neovascularization (CNV) and TAP/VIP compatible if
they followed the recommendation guidelines characteristics, group 1B, AMD with subfoveal CNV and TAP/
VIP incompatible, and group 1C, AMD with non-subfoveal CNV. The main outcomes were visual acuity
change, number of treatments and the comparison with the first year results.
Results: Of 56 eyes, 46 eyes (82.14%) had completed 24-month follow-up. Thirty-four eyes had CNV-related
AMD and 12 eyes were non-AMD. At the 24-month follow-up, mean visual acuity change in group 1A, 1B, 1C
were increased 0.25 (p = 0.13), 0.05 (p = 0.52), and 0.28 (p = 0.003), respectively. The total number of
treatments in the first and second year was 1.8 and 0.1 in group 1A, 2.3 and 0.1 in group 1B, 1.5 and 0.25 in
group 1C.
Conclusion: PDT was effective in Thai patients for the two-year follow-up even if they were not compatible
with TAP/VIP criteria. The treatment demonstrated stabilization or less visual loss in long-term results.
Keywords: Photodynamic therapy, Age-related macular degeneration, Thai patient
macular degeneration (AMD) and non-AMD in Thailand and to compare with the Treatment of Age-Related
Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP)
study.
Material and Method: The data of patients who received PDT between July 2003 and December 2004 and had
completed two-year follow-up were prospectively reviewed. Treated eyes were classified into two main groups,
the AMD (group 1) and non-AMD (group 2) groups. The AMD group was further divided into three
subgroups, group1A, AMD with subfoveal choroidal neovascularization (CNV) and TAP/VIP compatible if
they followed the recommendation guidelines characteristics, group 1B, AMD with subfoveal CNV and TAP/
VIP incompatible, and group 1C, AMD with non-subfoveal CNV. The main outcomes were visual acuity
change, number of treatments and the comparison with the first year results.
Results: Of 56 eyes, 46 eyes (82.14%) had completed 24-month follow-up. Thirty-four eyes had CNV-related
AMD and 12 eyes were non-AMD. At the 24-month follow-up, mean visual acuity change in group 1A, 1B, 1C
were increased 0.25 (p = 0.13), 0.05 (p = 0.52), and 0.28 (p = 0.003), respectively. The total number of
treatments in the first and second year was 1.8 and 0.1 in group 1A, 2.3 and 0.1 in group 1B, 1.5 and 0.25 in
group 1C.
Conclusion: PDT was effective in Thai patients for the two-year follow-up even if they were not compatible
with TAP/VIP criteria. The treatment demonstrated stabilization or less visual loss in long-term results.
Keywords: Photodynamic therapy, Age-related macular degeneration, Thai patient
Download:
PDF